Regeneron Shares Now Reflect Valuation as Pipeline Visibility Becomes Key, Morgan Stanley Says

MT Newswires Live

2025/12/03

Regeneron (REGN) is trading generally in line with Morgan Stanley's valuation, and further visibility on pipeline diversification will be important for investors, the firm said in a Wednesday note.

Progress with Eylea HD approvals and strong Dupixent sales have supported the stock's rebound this year, with Dupixent annualizing near $20 billion, the note added.

Morgan Stanley also said it is watching Eylea dynamics, including label enhancements and patient foundation support, as well as rising research and development spending as the company advances programs such as its F11 antibody.

Morgan Stanley downgraded Regeneron to equal-weight from overweight and maintained its $767 price target.

Shares of the company were down over 1% in recent Wednesday trading.

Price: 733.21, Change: -8.79, Percent Change: -1.18

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2588040155"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588040155\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588040155?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 23:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588040155","market":"hk","top_or_hot":-1,"title":"Regeneron Shares Now Reflect Valuation as Pipeline Visibility Becomes Key, Morgan Stanley Says","media":"MT Newswires Live","content":"<html><body><p> Regeneron (REGN) is trading generally in line with Morgan Stanley's valuation, and further visibility on pipeline diversification will be important for investors, the firm said in a Wednesday note.</p><p>Progress with Eylea HD approvals and strong Dupixent sales have supported the stock's rebound this year, with Dupixent annualizing near $20 billion, the note added.</p><p>Morgan Stanley also said it is watching Eylea dynamics, including label enhancements and patient foundation support, as well as rising research and development spending as the company advances programs such as its F11 antibody.</p><p>Morgan Stanley downgraded Regeneron to equal-weight from overweight and maintained its $767 price target.</p><p>Shares of the company were down over 1% in recent Wednesday trading.</p><p>Price: 733.21, Change: -8.79, Percent Change: -1.18</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron Shares Now Reflect Valuation as Pipeline Visibility Becomes Key, Morgan Stanley Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron Shares Now Reflect Valuation as Pipeline Visibility Becomes Key, Morgan Stanley Says\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-12-03 23:44</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Regeneron (REGN) is trading generally in line with Morgan Stanley's valuation, and further visibility on pipeline diversification will be important for investors, the firm said in a Wednesday note.</p><p>Progress with Eylea HD approvals and strong Dupixent sales have supported the stock's rebound this year, with Dupixent annualizing near $20 billion, the note added.</p><p>Morgan Stanley also said it is watching Eylea dynamics, including label enhancements and patient foundation support, as well as rising research and development spending as the company advances programs such as its F11 antibody.</p><p>Morgan Stanley downgraded Regeneron to equal-weight from overweight and maintained its $767 price target.</p><p>Shares of the company were down over 1% in recent Wednesday trading.</p><p>Price: 733.21, Change: -8.79, Percent Change: -1.18</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2362541513.USD","symbol_name":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2588040155","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588040155","pubTimestamp":1764776675,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Regeneron  is trading generally in line with Morgan Stanley's valuation, and further visibility on pipeline diversification will be important for investors, the firm said in a Wednesday note.Progress with Eylea HD approvals and strong Dupixent sales have supported the stock's rebound this year, with Dupixent annualizing near $20 billion, the note added.Morgan Stanley also said it is watching Eylea dynamics, including label enhancements and patient foundation support, as well as rising research and development spending as the company advances programs such as its F11 antibody.Morgan Stanley downgraded Regeneron to equal-weight from overweight and maintained its $767 price target.Shares of the company were down over 1% in recent Wednesday trading.Price: 733.21, Change: -8.79, Percent Change: -1.18","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0557290698.USD":"施罗德环球可持续增长基金","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","REGN":"再生元制药公司","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1548497426.USD":"安联环球人工智能AT Acc","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4585":"ETF&股票定投概念","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","BK4139":"生物科技","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","BK4127":"投资银行业与经纪业","LU0106831901.USD":"贝莱德世界金融基金A2","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","BK4516":"特朗普概念","LU0882574055.USD":"富达全球健康医疗A ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","BK4504":"桥水持仓","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0058720904.USD":"联博国际健康护理基金A","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H"},"translate_title":"摩根士丹利表示，随着管道可见性成为关键，再生元股价现在反映了估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":1},"content_text":"Regeneron (REGN) is trading generally in line with Morgan Stanley's valuation, and further visibility on pipeline diversification will be important for investors, the firm said in a Wednesday note.Progress with Eylea HD approvals and strong Dupixent sales have supported the stock's rebound this year, with Dupixent annualizing near $20 billion, the note added.Morgan Stanley also said it is watching Eylea dynamics, including label enhancements and patient foundation support, as well as rising research and development spending as the company advances programs such as its F11 antibody.Morgan Stanley downgraded Regeneron to equal-weight from overweight and maintained its $767 price target.Shares of the company were down over 1% in recent Wednesday trading.Price: 733.21, Change: -8.79, Percent Change: -1.18","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}